endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:
Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF.
You can contact us, or follow us on Twitter.
On 29 January 2025, the New England Journal of Medicine (NEJM) published the manuscript of the endTB clinical trial results. [...] The publication in the NEJM, a leading peer-reviewed medical journal that publishes cutting-edge research advancing global healthcare, reinforces the strong scientific value of the evidence produced by endTB.
After 3 years of preparation, the endTB data is now open for requests! The endTB Data Sharing Initiative (eDSI) aims to give ethical, equitable and transparent access to endTB data for a range of users who share the common goal of increasing information to improve care for MDR-TB patients. It will include data from the endTB Observational study, the endTB and endTB-Q clinical trials. Researchers, research institutions, PhD students, and other relevant users are invited to analyze a ready set of data on MDR-TB to benefit people with MDR-TB!
This comment on "Equitable, personalised medicine for tuberculosis: treating patients, not diseases" has been published in the Lancet Respiratory Medecine.
